48 publications
– Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators.
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
N Engl J Med. 2011 Mar 10;364(10):907-17.
– Girard SL, Gauthier J, Noreau A, Xiong L, Zhou S, Jouan L, Dionne-Laporte A, Spiegelman D, Henrion E, Diallo O, Thibodeau P, Bachand I, Bao JY, Tong AH, Lin CH, Millet B, Jaafari N, Joober R, Dion PA, Lok S, Krebs MO, Rouleau GA.
Increased exonic de novo mutation rate in individuals with schizophrenia.
Nat Genet. 2011 Jul 10;43(9):860-3. doi: 10.1038/ng.886.
– Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, Mazingue F, Lutz P, Vérité C, Berthou C, Galambrun C, Bernard F, Yacouben K, Bordigoni P, Edan C, Reguerre Y, Couillault G, Méchinaud F, Cayuela JM, Guilhot F.
Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
J Clin Oncol. 2011 Jul 10;29(20):2827-32.
– Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D’Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW.
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
J Natl Cancer Inst. 2011 Apr 6;103(7):553-61.
– Roy L, Tomowiak C, Guilhot F.
Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
Blood. 2011 Aug 29.
– Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R.
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Blood. 2011 Jul 21;118(3):686-92.
– Guilhot F, Guilhot J.
Predicting response in CML.
Blood. 2011 Feb 10;117(6):1773-4.
– Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, Melkus M, Bennaceur-Griscelli A, Guilhot F, Turhan AG.
Leukemic stem cell persistency in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.
Blood. 2011 Jul 25.
– Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O’Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS; NASH CRN; GIANT Consortium; MAGIC Investigators, Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB; GOLD Consortium.
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
PLoS Genet. 2011 Mar;7(3):e1001324.”
– Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, Legros L, Nicolini F, Rousselot P, Gardembas M, Helevaut N, Frimat C, Mahon FX, Guilhot F, Preudhomme C.
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.
Leukemia. 2011 Jun 3.
– Regnault N, Botton J, Heude B, Forhan A, Hankard R, Foliguet B, Hillier TA, Souberbielle JC, Dargent-Molina P, Charles MA; the EDEN Mother-Child Cohort Study Group.
Higher Cord C-Peptide Concentrations Are Associated With Slower Growth Rate in the 1st Year of Life in Girls but Not in Boys.
Diabetes. 2011 Aug;60(8):2152-9.
– Saulnier PJ, Roussel R, Halimi JM, Lebrec J, Dardari D, Maimaitiming S, Guilloteau G, Prugnard X, Marechaud R, Ragot S, Marre M, Hadjadj S;
SURDIAGENE, DIAB2NEPHROGENE, and DIABHYCAR study groups. Impact of natriuretic peptide clearance receptor (NPR3) gene variants on blood pressure in type 2 diabetes.
Diabetes Care. 2011 May;34(5):1199-204.
– Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Béné MC, Berger U, Büchner T, Burnett A, Cross NC, de Witte TJ, Döhner H, Dombret H, Einsele H, Engelich G, Foà R, Fonatsch C, Gökbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S; European LeukemiaNet.
The European LeukemiaNet: achievements and perspectives.
Haematologica. 2011 Jan;96(1):156-62.
– Abi Khalil C, Mohammedi K, Aubert R, Abou Jaoude E, Travert F, Hadjadj S, Fumeron F, Roussel R, Marre M.
Hyperadiponectinemia Is Independent of Kidney Function, Diabetes Duration, and Control in Type 1 Diabetic Patients without Microangiopathy.
J Clin Endocrinol Metab. 2011 Mar;96(3):E485-7.
– Couet W, Grégoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O.
Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80-mg Intravenous Dose of CMS in Young Healthy Volunteers.
Clin Pharmacol Ther. 2011 Jun;89(6):875-9.
– Couturier J, Paccalin M, Morel M, Terro F, Milin S, Pontcharraud R, Fauconneau B, Page G.
Prevention of the ß-amyloid peptide-induced inflammatory process by inhibition of double-stranded RNA-dependent protein kinase in primary murine mixed co-cultures.
J Neuroinflammation. 2011 Jun 23;8:72.
– Barron E, Migeot V, Rabouan S, Séby F, Ingrand I, M. Potin-Gautier M, Legube B. 2011
Selenium level exposure of subjects living in areas with high drinking water selenium : results of a french integrated exposure assessment survey.
Environmental International
– Wessman M, Forsblom C, Kaunisto MA, Söderlund J, Ilonen J, Sallinen R, Hiekkalinna T, Parkkonen M, Maxwell AP, Tarnow L, Parving HH, Hadjadj S, Marre M, Peltonen L, Groop PH; on behalf of the FinnDiane Study Group.
Novel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes.
PLoS One. 2011;6(9):e24053.
– Arroyo-Anlló EM, Ingrand P, Gil R
Improvement of semantic categorization through procedural learning in Alzheimer’s disease.
J Alzheimers Dis
– Tournoux-Facon C, Senellart H, Lemarie E, Tourani JM, Favrel S, Pouget JC, Pinel MC, Bennouna J.
Phase I and Pharmacokinetic Study of IV Vinflunine in Combination with Gemcitabine for Treatment of Advanced Non-small Cell Lung Cancer in Chemonaive Patients.
J Thorac Oncol. 2011 Jul;6(7):1247-53.
– Mouaffak F, Kebir O, Bellon A, Gourevitch R, Tordjman S, Viala A, Millet B, Jaafari N, Olié JP, Krebs MO.
Association of an UCP4 (SLC25A27) haplotype with ultra-resistant schizophrenia.
Pharmacogenomics. 2011 Feb;12(2):185-93.
– Jaafari N, Rigalleau F, Rachid F, Delamillieure P, Millet B, Olié JP, Gil R, Rotge JY, Vibert N.
A critical review of the contribution of eye movement recordings to the neuropsychology of OCD.
Acta Psychiatr Scand. 2011 Aug;124(2):87-101. doi: 10.1111/j.1600-0447.2011.01721.x.
– Möllsten A, Vionnet N, Forsblom C, Parkkonen M, Tarnow L, Hadjadj S, Marre M, Parving HH, Groop PH.
A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women.
Mol Genet Metab. 2011 May;103(1):66-70.
– Jaafari N, Frasca M, Rigalleau F, Rachid F, Gil R, Olié JP, Guehl D, Burbaud P, Aouizerate B, Rotgé JY, Vibert N; for Insight Study Group
Forgetting what you have checked: A link between working memory impairment and checking behaviors in obsessive-compulsive disorder.
Eur Psychiatry
– Thomas M, Clarhaut J, Strale PO, Tranoy-Opalinski I, Roche J, Papot S.
A galactosidase-responsive “”trojan horse”” for the selective targeting of folate receptor-positive tumor cells.
ChemMedChem. 2011 Jun 6;6(6):1006-10. doi: 10.1002/cmdc.201100114.
– Grinda M, Clarhaut J, Tranoy-Opalinski I, Renoux B, Monvoisin A, Cronier L, Papot S.
A Heterodimeric Glucuronide Prodrug for Cancer Tritherapy: the Double Role of the Chemical Amplifier.
ChemMedChem. 2011 Aug 3. doi: 10.1002/cmdc.201100355.
– Rigoard P, Buffenoir K, Jaafari N, Giot JP, Houeto JL, Mertens P, Velut S, Bataille B.
The accumbofrontal fasciculus in the human brain: a microsurgical anatomical study.
Neurosurgery
– Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, Fegueux N, Guilhot F, Lapusan S, Gratecos N, Cahn JY, Socié G, Yakoub-Agha I, Huynh A, Francois S, Bay JO, Maury S, Buzyn A, Contentin N, Mohty M.
Reduced-Intensity Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC.
Biol Blood Marrow Transplant. 2011 Jul 23.
– Abi Khalil C, Mohammedi K, Aubert R, Travert F, Hadjadj S, Roussel R, Fumeron F, Marre M.
Intensifying glycaemic control with insulin reduces adiponectin and its HMW isoform moderately in type 2, but not in type 1, diabetes.
Diabetes Metab. 2011 Jun;37(3):259-61.
– Erickson M, Jaafari N, Lysaker P.
Insight and negative symptoms as predictors of functioning in a work setting in patients with schizophrenia.
Psychiatry Res. 2011 Aug 1.
– Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, Pautas C, Berthou C, Guyotat D, Cony-Makhoul P, Gardembas M, Michallet M, Hayette S, Cayuela JM, Weiss IR, Réa D, Castaigne S, Mahon FX, Guilhot F, Rousselot P.
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Leuk Res. 2011 Jun;35(6):777-82.
– Kesse-Guyot E, Péneau S, Ferry M, Jeandel C, Hercberg S, Galan P; SU.VI.MAX 2 Research Group.
Thirteen-year prospective study between fish consumption, long-chain n-3 fatty acids intakes and cognitive function.
J Nutr Health Aging. 2011 Feb;15(2):115-20.
– Bourredjem A, Pelissolo A, Rotge JY, Jaafari N, Machefaux S, Quentin S, Bui E, Bruno N, Pochon JB, Polosan M, Baup N, Papetti F, Chéreau I, Arbus C, Mallet L, du Montcel ST; French “Stimulation dans le Trouble Obsessionnel Compulsif (STOC)
Study Group. A video clinical global impression scale (CGI) in obsessive compulsive disorder.
Psychiatry Res. 2011 Mar 30;186(1):117-22.
– Lebeau M, Mathoulin-Pélissier S, Bellera C, Tunon-de-Lara C, Daban A, Lipinski F, Jaubert D, Ingrand P, Migeot V; REPERES Group.
cancer care compared with clinical Guidelines: an observational study in France.
BMC Public Health.
– Tournoux-Facon C, De Rycke Y, Tubert-Bitter P.
Targeting population entering phase III trials: a new stratified adaptive phase II design.
Stat Med. 2011 Apr 15;30(8):801-11
– Maurel DB, Boisseau N, Ingrand I, Dolleans E, Benhamou CL, Jaffre C.
Combined effects of chronic alcohol consumption and physical activity on bone health: study in a rat model.
Eur J Appl Physiol. 2011 Mar 25.
– Jaafari N, Rachid F, Rotge JY, Polosan M, El-Hage W, Belin D, Vibert N, Pelissolo A.
Safety and efficacity of repetitive transcranial magnetic stimulation in the treatment of Obsessive-Compulsive Disorder : A review.
World J Biol Psychiatry. 2011 May 30.
– Jaafari N, Baup N, Bourdel MC, Olie JP, Rotge JY, Wassouf I, Sharov I, Millet B, Krebs MO.
Neurological Soft Signs in OCD patients with early age at onset compared with patients with schizophrenia and healthy subjects.
J Neuropsychiatry Clin Neurosci
– Jaafari N, Aouizerate B, Tignol J, El-Hage W, Wassouf I, Guehl D, Bioulac B, Daniel ML, Lacoste J, Gil R, Burbaud P, Rotge JY; Insight Study Group.
The Relationship between Insight and Uncertainty in Obsessive-Compulsive Disorder.
Psychopathology. 2011;44(4):272-6.
– Jouhet V, Defossez G, Burgun A, Le Beux P, Levillain P, Ingrand P, Claveau V.
Automated Classification of Free-text Pathology Reports for Registration of Incident Cases of Cancer.
Methods Inf Med. 2011 Jul 26;50(5).
– Ingrand I, Ingrand P, Gilbert-Dussardier B, Defossez G, Jouhet V, Migeot V, Dufour X, Klossek JM.
Altered quality of life in Rendu-Osler-Weber disease related to recurrent epistaxis.
Rhinology
– Kayemba-Kay’s S, Epstein S, Hindmarsh P, Burguet A, Ingrand P, Hankard R.
Does plasma IGF-BP3 measurement contribute to the diagnosis of growth hormone deficiency in children?
Ann Endocrinol
– Neau JP, Artaud-Uriot MS, Lhomme V, Bounaud JY, Lebras F, Boissonnot L, Moinot N, Ciron J, Larrieu D, Mathis S, Godeneche G, Ingrand P.
Vitamin D and multiple sclerosis. A prospective survey of patients of Poitou-Charentes area.
Rev Neurol
– Saulnier PJ, Roussel R, Halimi JM, Lebrec J, Dardari D, Maimaitiming S, Guilloteau G, Prugnard X, Marechaud R, Ragot S, Marre M, Hadjadj S; SURDIAGENE, DIAB2NEPHROGENE, and DIABHYCAR study groups.
Impact of natriuretic peptide clearance receptor (NPR3) gene variants on blood pressure in type 2 diabetes.
EDNSG meeting 2011 Ljubjana Slovenia
– S Hadjadj, A Miot, S Ragot, W Hammi, PJ Saulnier, P Sosner, X Piguel, R Marechaud
Prognostic value of resting heart rate on renal outcomes in type 2 diabetic patients: a competing risk analysis in a prospective cohort.
ADA 2012 Philadephia USA
– Bellarbre F, Baudemont C, Tartarin F, Migeon-Duballet I, Merlet-Chicoine I, Paccalin M.
Evaluation de l’incidence et des caractéristiques des effets secondaires des traitements spécifiques de la maladie d’Alzheimer en consultation mémoire.
– Michaud-Herbst A, Jouhet V, Ingrand P, Letard JC, Dupuychaffray JP, Barrioz T, Beauchant M; for the Poitou-Charentes Gastroenterologist Network.
Evaluation of French guidelines on the indications of colonoscopy: Results of a regional practice survey.
Clin Res Hepatol Gastroenterol.
– Mok E, Hankard R.
Glutamine supplementation in sick children: is it beneficial?
J Nutr Metab.